0KBU.LSE Omeros Corporation

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
5.6x
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Is 0KBU.LSE undervalued?

Graham number

The Graham number of Omeros Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Omeros Corporation fundamental analysis

No fundamental analysis for Omeros Corporation yet.

Omeros Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Omeros Corporation

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also deve…

Full company profile